ide-cel (formerly bb2121) anti-bcma car t-cell therapy in relapsed/refractory mm
Published 7 years ago • 269 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
3:17
anti-bcma car t-cells for mm: durable clinical responses with ide-cel (formerly bb2121)
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
2:28
bb21217: next gen anti-bcma car-t for r/r mm
-
1:43
ide-cel therapy for multiple myeloma with renal impairment
-
2:54
an overview of a study of bb2121 in multiple myeloma
-
2:15
updates on ide-cel and cilta-cel for myeloma
-
7:03
updated results of the idecabtagene vicleucel (ide-cel bb2121) crb-401 trial in rr multiple myeloma
-
2:31
integrating bcma-targeted agents in earlier lines of therapy for r/r multiple myeloma
-
1:28
real-world experience: ide-cel for r/r multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
11:27
anti-bcma car t cell therapy for multiple myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
4:57
idecabtagene vicleucel for r/r myeloma
-
5:51
safety of hbi0101 (nxc-201), a novel academic anti-bcma car-t, in r/r al amyloidosis
-
2:58
bcma 2 1 t-cell engager cc-93269 in patients with r/r myeloma
-
4:34
what is ide-cel and how can it benefit myeloma patients?
-
2:19
improving global access to novel immunotherapies for patients with r/r dlbcl
-
5:05
crb-401: ide-cel for r/r multiple myeloma
-
5:15
the promise of immunotherapies in t-cell lymphoma